A review of signaling lymphocytic activation molecule (SLAM) family proteins by Dragovich and Mor (2018) suggested that SLAMF9 was a potential therapeutic target for inflammatory and autoimmune diseases. This evidence concerns the gene SLAMF9 and autoimmune disease.